Evidence map›Paper›PMID 41752104›Full record

ArticleInternational journal of molecular sciences2026

Anticancer Acridones, Part 2-Acronycine-Type Derivatives Modified with 2,5-Dihydro-1,2,4-Triazine Moiety: Synthesis and In Vitro Evaluation.

Andrey A Zonov, Ramil F Fatykhov, Igor A Khalymbadzha, Ainur D Sharapov, Anastasia P Potapova, Ilya I Butorin, Vsevolod V Melekhin, Anastasia V Paramonova, Emiliya V Nosova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrey A ZonovDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.
Ramil F FatykhovDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.ORCID 0000-0003-3129-8658
Igor A KhalymbadzhaDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.
Ainur D SharapovDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.ORCID 0000-0003-1582-5462
Anastasia P PotapovaDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.
Ilya I ButorinDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.ORCID 0000-0003-3403-5079
Vsevolod V MelekhinDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.
Anastasia V ParamonovaDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.ORCID 0009-0007-4268-8113
Emiliya V NosovaDepartment of Organic and Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia.ORCID 0000-0002-0177-1582

Funding

grant of the state program of the «Sirius» Federal Territory «Scientific and technological devel-opment of the «Sirius» Federal Territory» Agreement 30-03 of 7 July 2025Ministry of Science and Higher Education of the Russian Federation FEUZ-2023-002
6 · The paper itself

Abstract

This manuscript presents the synthesis of eight novel noracronycine derivatives containing 1,2,4-triazine moiety and evaluates their anticancer activity in vitro. The obtained compounds exhibit activity in the micromolar range and show selectivity towards glioblastoma A172 and breast cancer Hs578T cells. Compounds incorporating a dihydrotriazine moiety demonstrate an enhanced anticancer profile when compared to a noracronycine derivative lacking a triazine substituent. Furthermore, introducing a pyridyl group into the triazine core increases selective cytotoxicity toward cancerous cells. The lead compound exhibits an IC

Indexed as

AcridonesAntineoplastic AgentsTriazinesApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity Relationship1,2,4-triazineAcridonesAntineoplastic AgentsTriazines1,2,4-triazineacronycineanticancer activitylate-stage modification

Identifiers

PMID41752104
PMCPMC12940183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.